| 000 | 01749 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517224054.0 | ||
| 264 | 0 | _c20200907 | |
| 008 | 202009s 0 0 eng d | ||
| 022 | _a1522-9645 | ||
| 024 | 7 |
_a10.1093/eurheartj/ehy347 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFox, K A A | |
| 245 | 0 | 0 |
_aAnti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? _h[electronic resource] |
| 260 |
_bEuropean heart journal _c05 2019 |
||
| 300 |
_a1466-1471 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAspirin _xadverse effects |
| 650 | 0 | 4 |
_aAtherosclerosis _xcomplications |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDeath |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aFactor Xa Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xadverse effects |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMyocardial Infarction _xepidemiology |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aRivaroxaban _xadverse effects |
| 650 | 0 | 4 |
_aSecondary Prevention _xmethods |
| 650 | 0 | 4 |
_aStroke _xepidemiology |
| 650 | 0 | 4 |
_aThrombosis _xprevention & control |
| 650 | 0 | 4 |
_aVascular Diseases _xpathology |
| 700 | 1 | _aEikelboom, J W | |
| 700 | 1 | _aAnand, S S | |
| 700 | 1 | _aBhatt, D L | |
| 700 | 1 | _aBosch, J | |
| 700 | 1 | _aConnolly, S J | |
| 700 | 1 | _aHarrington, R A | |
| 700 | 1 | _aSteg, P G | |
| 700 | 1 | _aYusuf, S | |
| 773 | 0 |
_tEuropean heart journal _gvol. 40 _gno. 18 _gp. 1466-1471 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/eurheartj/ehy347 _zAvailable from publisher's website |
| 999 |
_c28571935 _d28571935 |
||